7 results on '"Carlsson, Katarina Steen"'
Search Results
2. Area under the curve: Comparing the value of factor VIII replacement therapies in haemophilia A.
- Author
-
Persson, Sofie, Berndt, Cecilia, Engstrand, Sara, Trinczek, Annegret, Carlsson, Katarina Steen, and Berntorp, Erik
- Subjects
BLOOD coagulation factor VIII ,HEMOPHILIA ,PRICES ,MEDICAL economics ,SENSITIVITY analysis - Abstract
Introduction: In factor VIII (FVIII) prophylaxis for haemophilia A, cost comparisons have used price per international unit (IU) based on the once reasonable assumption of equivalent outcome per IU. Now, with several extended half‐life (EHL) products available, new outcome‐oriented ways to compare products are needed. Area under the curve (AUC) quantifies FVIII levels over time after infusion providing comparable data. Aim: To develop a decision analytical model for making indirect comparisons of FVIII replacement products based on AUC. Methods: A literature search identified 11 crossover studies with relevant pharmacokinetic data. A common comparator FVIII level curve was calculated using pooled data from selected studies. Absolute curves for other products were estimated based on relative differences to the common comparator (% difference vs the anchor). Three scenarios were investigated: (1) Kogenate® versus Kovaltry® and Jivi®; (2) Advate® versus Elocta®, NovoEight®, Kovaltry, Adynovate®, Afstyla®, and ReFacto®; and (3) Jivi versus Elocta, Adynovate, and Kogenate. Sensitivity analyses investigated effects of assay type and dose. Results: In scenario 1, Jivi (+50%) and Kovaltry (+14%) showed larger AUCs versus Kogenate. In scenario 2, EHL products, Elocta and Adynovate, had the largest AUC (+64% and +58%, respectively) versus Advate. Compared with all other products in scenario 3, Jivi had the largest AUC by +13%–28%. Conclusion: This analysis concludes that EHL products differ in relative AUC, have a larger AUC compared with standard half‐life, and thus, different FVIII levels over time after infusion. This model may aid decision makers in the absence of head‐to‐head data. [ABSTRACT FROM AUTHOR] more...
- Published
- 2023
- Full Text
- View/download PDF
Catalog
3. Preparing for tomorrow: Defining a future agenda.
- Author
-
O'Mahony, Brian, Wong, Olivier, Eichler, Hermann, Neumann, Peter, Carlsson, Katarina Steen, and Noone, Declan
- Subjects
GENE therapy ,TECHNOLOGY assessment ,MEDICAL technology ,HEMOPHILIA - Abstract
Gene therapy will be the first long‐term therapy with potential to produce a functional cure for haemophilia. As a single dose ('once‐and‐done') therapy with significant uncertainties regarding impact and duration of factor expression, flexibility and adaptability of (1) value framework, (2) health technology assessment (HTA) methodology, and (3) development of alternative payment models will be needed for adoption of this new technology and to facilitate transparent decision‐making to support its implementation. The responsibility for each of these currently lies with distinct entities, underscoring a need for enhanced collaboration between all stakeholders, as expanded engagement by key stakeholders will be critical to optimizing the assessment of value, enabling an optimised approach to HTA, and opening receptivity to new and innovative payment models. This supplement issue describes important considerations for a gene therapy 'toolkit', highlighting key considerations for each of the aforementioned tools, which will be useful for guiding decision‐making regarding gene therapy as a novel treatment modality. In this article, we outline how the tools presented in this supplement can be applied as part of a framework to address the requirements of the relevant stakeholders, including payers, manufacturers, treaters, and patients. The paper also provides an illustrative example of how to understand the features of alternative payment models depending on the organization of and payment for healthcare. [ABSTRACT FROM AUTHOR] more...
- Published
- 2022
- Full Text
- View/download PDF
4. Joint comorbidities among Swedish carriers of haemophilia: A register‐based cohort study over 22 years.
- Author
-
Osooli, Mehdi, Donfield, Sharyne M., Carlsson, Katarina Steen, Baghaei, Fariba, Holmström, Margareta, Berntorp, Erik, and Astermark, Jan
- Subjects
X chromosome ,COHORT analysis ,AGE of onset ,COMORBIDITY - Abstract
Background: A significant fraction of women with an impaired factor VIII or IX gene in the X chromosome, carriers of haemophilia, will have clotting factor activities corresponding to those seen in males with non‐severe haemophilia, hence, experience an increased bleeding tendency. Data describing the long‐term joint outcomes among carriers are limited. We compared the age at onset, frequency of joint‐related diagnoses as well as joint surgery and related hospitalizations among carriers of haemophilia with sex‐ and birthdate‐matched controls from the general population. Methods: Carriers of haemophilia born 1941‐2008 were identified through the haemophilia treatment centres' (HTCs) databases and the National Patient Register of Sweden. For each carrier, we included up to five individuals using the Swedish population register as comparisons. Data for the period 1987‐2008 were obtained. Results: Among 539 potential carriers identified, 213 had a known factor activity. Carriers with reduced factor activity and those with unknown factor activity had received their first joint‐related diagnosis at a significantly earlier age than their comparisons. The same subgroups showed an overall 2.3‐ and 2.4‐fold higher hazard for joint‐related diagnoses compared with the general population. In addition, the hazards of joint‐related outpatient hospitalization were 3.2‐fold (95% CI: 1.2, 9.1) and 2.5‐fold (95% CI: 1.6, 3.7). This was not observed for those with normal factor activity. Conclusion: Carriers of haemophilia suffer a significant risk for joint comorbidities. This risk seems to correlate to the factor activity. Our findings underline the importance of regular clinical follow‐up of carriers at HTCs. [ABSTRACT FROM AUTHOR] more...
- Published
- 2019
- Full Text
- View/download PDF
5. The first Team Haemophilia Education meeting, 2015, Amsterdam, The Netherlands.
- Author
-
Berntorp, Erik, Hart, Daniel, Mancuso, Maria Elisa, d'Oiron, Roseline, Perry, David, O'Mahony, Brian, Kaczmarek, Radoslaw, Crato, Miguel, Pasi, John, Miners, Alec, Carlsson, Katarina Steen, Kitchen, Steve, Boehlen, Françoise, Giangrande, Paul, Cebura, Elizabete, Uitslager, Nanda, Osooli, Mehdi, Janeckova, Daniela, Haldon, Rosie, and Rivolta, Gianna Franca more...
- Subjects
HEMOPHILIA ,BLOOD coagulation disorders ,PHARMACOKINETICS ,MEDICAL personnel ,EDUCATION ,CONFERENCES & conventions ,BLOOD disease treatment - Abstract
Haemophilia remains a complex disorder to diagnose and manage, requiring close cooperation between multidisciplinary healthcare professionals. There are still many unmet challenges in haemophilia care. The first Team Haemophilia Education ( THE) meeting, held on 7-8 May 2015 in Amsterdam, The Netherlands, aimed to promote the optimal care of haemophilia patients through education of the multidisciplinary treatment team. This was achieved by reviewing the latest developments in haemophilia management, considering how these can be implemented in the clinic to improve patient care and providing a platform for networking and debate for all haemophilia treatment team members. Haemophilia treatment centres from several countries were asked to complete a premeeting online questionnaire to establish the biggest challenges that they face when managing patients. The concerns expressed were used to develop the agenda, which comprised a combination of formal presentations, case studies and informal workshops covering such topics as pharmacokinetics, laboratory assays and tailoring of treatment to individual patients. This report is a summary of the key developments in haemophilia care presented by various investigators and healthcare professionals at THE meeting 2015. [ABSTRACT FROM AUTHOR] more...
- Published
- 2016
- Full Text
- View/download PDF
6. Predicting Changes in Cardiovascular Risk Factors in Type 2 Diabetes in the Post-UKPDS Era: Longitudinal Analysis of the Swedish National Diabetes Register.
- Author
-
Kiadaliri, Aliasghar Ahmad, Clarke, Philip M., Gerdtham, Ulf-G., Nilsson, Peter, Eliasson, Björn, Gudbjörnsdottir, Soffia, and Carlsson, Katarina Steen
- Subjects
CARDIOVASCULAR diseases risk factors ,TYPE 2 diabetes ,DIABETES complications ,LONGITUDINAL method ,REPORTING of diseases ,PUBLIC health - Abstract
The aim of the current study was to provide updated time-path equations for risk factors of type-2-diabetes-related cardiovascular complications for application in risk calculators and health economic models. Observational data from the Swedish National Diabetes Register were analysed using Generalized Method of Moments estimation for dynamic panel models (N = 5, 043, aged 25-70 years at diagnosis in 2001-2004). Validation was performed using persons diagnosed in 2005 (n = 414). Results were compared with the UKPDS outcome model. The value of the risk factor in the previous year was the main predictor of the current value of the risk factor. People with high (low) values of risk factor in the year of diagnosis experienced a decreasing (increasing) trend over time. BMI was associated with elevations in all risk factors, while older age at diagnosis and being female generally corresponded to lower levels of risk factors. Updated time-path equations predicted risk factors more precisely than UKPDS outcome model equations in a Swedish population. Findings indicate new time paths for cardiovascular risk factors in the post-UKPDS era. The validation analysis confirmed the importance of updating the equations as new data become available; otherwise, the results of health economic analyses may be biased. [ABSTRACT FROM AUTHOR] more...
- Published
- 2013
- Full Text
- View/download PDF
7. Metabolic control, healthcare satisfaction and costs 1 month after diagnosis of type 1 diabetes: a randomised controlled trial of hospital-based care vs. hospital-based home care.
- Author
-
Tiberg, Irén, Carlsson, Katarina Steen, Carlsson, Annelie, and Hallström, Inger
- Subjects
HOME care services ,PATIENT satisfaction ,ACADEMIC medical centers ,SIBLINGS ,CLINICAL trials ,DIABETES ,EMERGENCY medicine ,FAMILIES ,GLYCOSYLATED hemoglobin ,HEALTH services accessibility ,EVALUATION of medical care ,TYPE 1 diabetes ,MEDICAL care costs ,PARENTS ,PEDIATRICS ,U-statistics ,DIAGNOSIS - Abstract
Procedures for the initial management of children newly diagnosed with diabetes vary greatly worldwide and the evidence available is insufficient for conclusively determining the best process regarding hospital-based or home-based care. The aim of the study was to compare two different regimens for children with newly diagnosed type 1 diabetes; hospital-based care and hospital-based home care ( HBHC), defined as specialist care in a home-based setting. A randomised controlled trial, including 60 children, took place at a university hospital in Sweden during the period of March 2008 to September 2011. After 2-3 d with hospital-based care, children from 3 to 15 yr of age were randomised to either continued hospital-based care for a total of 1-2 wk or to HBHC. This article presents results 1 month after diagnosis. No differences were shown in the daily mean glucose level or in its variability when the children received care but, after discharge, children who received HBHC showed lower mean plasma glucose values and lower variability compared to children who received hospital-based care. Children in HBHC had fewer episodes of hypoglycaemia during the first month after diagnosis. In the HBHC group, parents were more satisfied with the healthcare received and healthcare costs for the first month were 30% lower as compared to hospital-based care. The results 1 month after diagnosis support the HBHC programme as being a safe and cost-effective way of providing care. A follow-up will continue for 2 yr to evaluate which process was best for the majority of families over time. [ABSTRACT FROM AUTHOR] more...
- Published
- 2012
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.